Lipocine (NASDAQ:LPCN) Shares Pass Above Fifty Day Moving Average – Here’s What Happened

Shares of Lipocine Inc. (NASDAQ:LPCN) crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $2.31 and traded as high as $2.37. Lipocine shares last traded at $2.29, with a volume of 30,358 shares trading hands.

Analyst Upgrades and Downgrades

LPCN has been the topic of a number of recent analyst reports. Weiss Ratings lowered Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 18th. HC Wainwright reiterated a “neutral” rating on shares of Lipocine in a research report on Monday, April 6th. Finally, Wall Street Zen cut shares of Lipocine from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $15.00.

Lipocine Stock Down 3.0%

The company has a market cap of $18.88 million, a P/E ratio of -1.22 and a beta of 0.44. The business has a 50-day moving average price of $2.31 and a two-hundred day moving average price of $5.35.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The firm had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.16 million. Lipocine had a negative return on equity of 66.70% and a negative net margin of 571.18%. As a group, sell-side analysts expect that Lipocine Inc. will post -1.91 EPS for the current fiscal year.

Institutional Investors Weigh In On Lipocine

Several institutional investors have recently modified their holdings of LPCN. Citadel Advisors LLC bought a new stake in shares of Lipocine during the 3rd quarter valued at $41,000. Jane Street Group LLC bought a new stake in shares of Lipocine in the 4th quarter valued at about $85,000. Dimensional Fund Advisors LP raised its position in shares of Lipocine by 57.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock valued at $153,000 after acquiring an additional 6,982 shares during the period. ADAR1 Capital Management LLC acquired a new stake in shares of Lipocine in the 1st quarter valued at approximately $185,000. Finally, Renaissance Technologies LLC raised its position in shares of Lipocine by 3.6% in the 4th quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock valued at $300,000 after acquiring an additional 1,300 shares during the period. Institutional investors and hedge funds own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.